Recent advances in immune-related therapies for bullous pemphigoid
LV Yansi
WANG Bin
GUAN Lvxin
GAN Ziqin
WEN Ziping
YU Na
MA Li
XUE Ruzeng
HOU Suchun
Abstract：Bullous pemphigoid(BP)is a common autoimmune blistering skin disease charac-terized by tense blisters and severe pruritus,significantly impacting the quality of life of affected patients.Treatment strategies have expanded from conventional corticosteroids and immunosup-pressants to novel immunomodulatory agents.These include targeting B cells therapies(ritux-imab),IgE(omalizumab),Th2 axis(dupilumab),complement system(sutimlimab,avdoralim-ab),eosinophils(bertilimumab,benralizumab),and Th 17 axis(ustekinumab,tildrakizumab).These therapies have shown promising efficacy in refractory BP,reducing corticosteroid depend-ence and alleviating itching.Combination therapy strategies and low-dose IL-2 provide additional options for patients with immune checkpoint inhibitor-related BP(ICI-BP).This article systemati-cally reviews advancements in immunological treatments for both BP and ICI-BP,including their mechanisms of action and safety profiles,providing references to optimize clinical management.
Keywords：bullous pemphigoidautoimmuneimmunomodulatorsimmunosuppressants
Publication Date：2025-11-28
Online Publishing Date：2025-12-29(First online date of this platform, not the publication date of the document)
Pages：7( 830-836 )